Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003662 · ClinicalTrials.gov registry record · Phase 2
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
A Phase 2 study of Leukemia and Myelodysplastic Syndromes, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 15
- Study locations
NCT00003662 is a Phase 2 study of Leukemia and Myelodysplastic Syndromes that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 90 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (82% lower). The trial reports 15 study locations across 9 states.
The verdict
NCT00003662, a Phase 2 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 15
- Study locations
Study Summary
RATIONALE: Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation in treating patients who have hematologic cancer or other hematologic or metabolic diseases.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG melphalan
- DRUG busulfan
- DRUG cyclosporine
- BIOLOGICAL anti-thymocyte globulin
Study Locations (15)
Florida
- University of Florida Health Science Center - Gainesville
- Division of Pediatric Surgery - Jacksonville
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- University of Chicago Cancer Research Center - Chicago
New York
- Roswell Park Cancer Institute - Buffalo
- New York Blood Center - New York
North Carolina
- Lineberger Comprehensive Cancer Center, UNC - Chapel Hill
- Duke Comprehensive Cancer Center - Durham
South Carolina
- Medical University of South Carolina - Charleston
- University of South Carolina School of Medicine - Columbia
Louisiana
- Children's Hospital of New Orleans - New Orleans
Missouri
- Cardinal Glennon Children's Hospital - St Louis
New Jersey
- Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 1998-08 |
| Est. Completion | 2001-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003662
The ClinicalTrials.gov registry entry for NCT00003662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (82% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003662 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00003662 about?
NCT00003662 is a clinical study titled "Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases". RATIONALE: Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy or radiation therapy. PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood transplantation in treating patients who have hematologic cancer or other hematologic or metabolic ...
What is the current status of trial NCT00003662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 1998-08. Estimated completion is 2001-01.
What conditions does trial NCT00003662 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes, Graft-Versus-Host Disease, Thymic Carcinoma.
What interventions are being tested in trial NCT00003662?
The interventions under investigation include: cyclophosphamide (DRUG), melphalan (DRUG), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003662?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003662 being conducted?
This trial has 15 study locations across Florida, Illinois, Louisiana, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.